Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
PHASE3CompletedINTERVENTIONAL
Enrollment
121
Participants
Timeline
Start Date
October 27, 2014
Primary Completion Date
November 7, 2019
Study Completion Date
November 7, 2019
Conditions
ANCA-associated Primary Necrotizing Vasculitides
Interventions
DRUG
Rosuvastatin
Rosuvastatin 20 mg/day
DRUG
Placebo
Placebo
Trial Locations (1)
75014
Hopital Cochin, Paris
All Listed Sponsors
lead
Assistance Publique - Hôpitaux de Paris
OTHER
NCT02117453 - Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides | Biotech Hunter | Biotech Hunter